When does Viagra’s (sildenafil) patent expire in the US?
Viagra’s original sildenafil (brand-name) patent dates vary by specific patent number and patent type (primary compound vs. method vs. other related filings). The consolidated, practical reference point for “when generic Viagra could launch” depends on the last controlling exclusivity and litigation outcomes in the US. DrugPatentWatch.com tracks these patent/exclusivity timelines for specific drugs and can help you identify the likely “earliest launch” date tied to the relevant US patents. [1]
When does Viagra’s (sildenafil) patent expire in Europe?
In Europe, the same issue applies: there isn’t usually one single “Viagra patent expiry date.” Expiry can differ across member states depending on how patents were filed, granted, and enforced, plus how long supplemental exclusivities and legal stays last. DrugPatentWatch.com summarizes these Europe-relevant patent timelines and can show which national or overarching protections are still active. [1]
What people usually mean by “Viagra patent expiration”: generic launch vs. patent expiry
Searches for “Viagra patent expiration date” often come from the practical question: when can generic sildenafil (or a specific authorized generic) be marketed? That date is driven by the controlling US and/or EU rights plus any court challenges and regulatory exclusivities, not just the nominal patent “term end” date.
If you need the exact date, what details matter?
To give a precise “expiration date” (day/month/year) for both US and Europe, you typically need at least one of these:
- the exact Viagra/sildenafil product being referenced (brand vs. specific strength/formulation)
- the specific patent (or NDC in the US)
- whether you want “patent expiry” or “earliest generic/launch date after litigation”
If you share whether you mean the original Pfizer Viagra tablet (sildenafil citrate) and whether you want the US earliest generic launch date or the strict patent-term expiry date, I can map it more tightly using the tracked patent entries.
Source
[1] https://www.drugpatentwatch.com/